Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Rollema

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
International Journal of Pharmaceutics|February 5, 2025
In vitro studies on stability and phosphatase activity of the anticancer agent LB-100 and its active hydrolysis product endothallHans Rollema, Robert Volkmann, Panayiotis Zagouras, et al.
Behavioural Pharmacology|May 14, 2011
α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like propertiesYann S Mineur, Emily B Einstein, Patricia A Seymour, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposuresKarthik Venkatakrishnan, Elaine Tseng, Frederick R Nelson, et al.
Toxicology and Applied Pharmacology|September 25, 2012
Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetineAnthony A Fossa, Todd A Wisialowski, Thomas Cremers, et al.
European Journal of Pharmacology|January 4, 2005
The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine releaseDavid E Johnson, Frank M Nedza, Douglas K Spracklin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 5, 2010
Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in ratsSusmita Chatterjee, Pia Steensland, Jeffrey A Simms, et al.
Diabetes|April 28, 2005
Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemiaDavid E Johnson, Hanae Yamazaki, Karen M Ward, et al.
Schizophrenia Bulletin|August 16, 2008
Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulationYvette E Savoy, Michael A Ashton, Matthew W Miller, et al.
Biochemical Pharmacology|June 9, 2009
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognitionHans Rollema, Mihály Hajós, Patricia A Seymour, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2005
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisineJotham W Coe, Michael G Vetelino, Crystal G Bashore, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
International Journal of Pharmaceutics|February 5, 2025
In vitro studies on stability and phosphatase activity of the anticancer agent LB-100 and its active hydrolysis product endothallHans Rollema, Robert Volkmann, Panayiotis Zagouras, et al.
Behavioural Pharmacology|May 14, 2011
α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like propertiesYann S Mineur, Emily B Einstein, Patricia A Seymour, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposuresKarthik Venkatakrishnan, Elaine Tseng, Frederick R Nelson, et al.
Toxicology and Applied Pharmacology|September 25, 2012
Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetineAnthony A Fossa, Todd A Wisialowski, Thomas Cremers, et al.
European Journal of Pharmacology|January 4, 2005
The role of muscarinic receptor antagonism in antipsychotic-induced hippocampal acetylcholine releaseDavid E Johnson, Frank M Nedza, Douglas K Spracklin, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 5, 2010
Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in ratsSusmita Chatterjee, Pia Steensland, Jeffrey A Simms, et al.
Diabetes|April 28, 2005
Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemiaDavid E Johnson, Hanae Yamazaki, Karen M Ward, et al.
Schizophrenia Bulletin|August 16, 2008
Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulationYvette E Savoy, Michael A Ashton, Matthew W Miller, et al.
Biochemical Pharmacology|June 9, 2009
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognitionHans Rollema, Mihály Hajós, Patricia A Seymour, et al.
Bioorganic & Medicinal Chemistry Letters|May 24, 2005
In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisineJotham W Coe, Michael G Vetelino, Crystal G Bashore, et al.
Pageof 4